Research programme: parasitic infections therapeutics - Astellas/Tokyo Institute of Technology
Latest Information Update: 28 Nov 2018
At a glance
- Originator Astellas Pharma; Tokyo Institute of Technology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Leishmaniasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Japan
- 30 Jul 2012 Early research in African trypanosomiasis in Japan (unspecified route)